Eli Lilly has recently achieved one of the most impressive quarters in the history of the pharmaceutical industry. Despite this remarkable performance, its stock price lingers below its peak of the past year. An in-depth examination of its pipeline and valuation suggests that even greater opportunities could lie ahead.
Analyzing Recent Performance
In its second quarter of 2026, Eli Lilly reported a staggering 48% year-over-year revenue growth, reaching $22.974 billion. Notably, the blockbuster drug Mounjaro contributed $9.943 billion to this total, and the company has raised its full-year earnings per share (EPS) guidance to between $35.50 and $36.50. However, despite these impressive numbers, shares closed at $1,156.73, reflecting only an 8.16% increase since the start of the year. This raises a pivotal question: Can Lilly’s stock reach $1,500 per share by late 2027?
Stock Performance vs. Market Sentiment
The stock’s recent performance does not seem to align with its business results. Over the last week, shares fell by 7.23%, and only a modest 0.83% increase was recorded over the past month. Moreover, the stock currently trades below its 52-week high of $1,292.65, and with a beta of just 0.506, it appears less susceptible to market sentiment fluctuations.
Two key factors are contributing to this stagnation. Firstly, U.S. realized prices for Lilly’s products dropped by 13% in Q2, raising concerns among investors regarding pricing pressures from payers. Secondly, the second quarter’s financials were impacted by $2.78 billion in acquired in-process research and development expenses stemming from a series of acquisitions, which obscured the underlying earnings potential.
Wall Street Perspectives and Forecasts
The consensus target price on Wall Street stands at $1,315.04, based on a mixture of 5 strong buys, 17 buys, 4 holds, 1 sell, and 1 strong sell. While this reflects a generally positive outlook, the expected upside appears limited to the mid-teens percentage range. In contrast, a more optimistic valuation model suggests a base case target of $1,398.96, with bullish and bearish cases at $1,456.80 and $1,170.32, respectively.
Confidence in these projections is notably high, supported by a bullish analyst sentiment score of 79 and a quarterly earnings growth rate of 26.2%. Analysts may be overly focused on current price performance rather than the anticipated EPS power in 2027, creating an opportunity for savvy investors.
Path to the $1,500 Target
Achieving a stock price of $1,500 from the current $1,156.73 represents a 29.7% increase. With a forward EPS estimate of $38.38, this target would translate to a forward price-to-earnings (P/E) ratio of 39. In comparison, the base case target of $1,398.96 suggests a P/E of 36. Therefore, reaching the ambitious $1,500 target would necessitate some expansion in the multiple.
This growth is plausible if the company’s pipeline delivers on its potential. Several catalysts could support this trajectory: the anticipated FDA approval of Mounjaro for cardiovascular risk reduction, promising Phase 3b data on Zepbound in combination with Taltz, and the acquisition of Merida Biosciences. However, the most significant driver may be retatrutide, which CEO David Ricks emphasized as central to Lilly’s ongoing momentum.
Current Valuation vs. Earnings Power
At $1,156.73 and with a forward EPS of $38.38, Lilly trades at around 30 times its forward earnings. This valuation is reasonable for a company experiencing substantial revenue growth of 48% and boasting gross margins of 85.8%. The stock has shown remarkable growth, returning over 1,660.11% over the past decade, and if EPS reaches the consensus estimate of $47.23 by 2027, the current valuation could appear attractive.
Conditions for Success
To reach the $1,500 target, several conditions need to be met. The timely submission of retatrutide’s biologics license application (BLA) in Q1 2027 is crucial. Additionally, the Foundayo platform must successfully scale from its early adoption phase, currently boasting 36,000 prescribers. Finally, it is essential for international incretin growth to sustain the remarkable 74% rate achieved in 2026. Any delays in regulatory approvals or significant pricing disruptions in the GLP-1 market could hinder progress.
Conclusion
Eli Lilly stands at a pivotal moment, with its record stock price masking a wealth of untapped potential. While the path to $1,500 by 2027 is fraught with challenges, it is certainly within reach given the right developments within its pipeline. As the pharmaceutical landscape evolves, Lilly’s innovative strategies and robust product offerings could make it one of the most promising investments of the decade.
- Eli Lilly achieved 48% revenue growth in Q2 2026.
- Current stock price suggests limited upside, but potential exists for significant gains.
- Key catalysts include FDA approvals and successful product launches.
- Valuation appears attractive based on projected future earnings.
- Successful execution of strategic plans is crucial for reaching $1,500 per share.
Read more → 247wallst.com